iBio, Inc. Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2016, filed October 13, 2016. The requested “2015 Q4” does not match this annual filing; the filing compares fiscal 2016 with fiscal 2015.
Business Context
iBio is a biotechnology company commercializing plant-based protein-expression technologies, including iBioLaunch and iBioModulator, for vaccines and therapeutic proteins. The company also develops selected product candidates, principally IBIO-CFB03 for fibrotic diseases, and provides development, manufacturing and technology-transfer services.
In January 2016, iBio formed iBio CMO LLC with an affiliate of Eastern Capital Limited. iBio retained a 70% interest and Eastern contributed $15 million for a 30% interest. Commercial operations began in January 2016 at a Bryan, Texas facility under a 34-year sublease.
Financial Highlights
| Metric | FY2016 | FY2015 | Change |
|---|---|---|---|
| Revenue | $0.948 million | $1.851 million | Down $0.903 million |
| Operating loss | $9.893 million | $6.666 million | Loss increased $3.227 million |
| Consolidated net loss | $10.657 million | $6.625 million | Loss increased $4.032 million |
| Net loss attributable to iBio | $9.764 million | $6.625 million | Loss increased $3.139 million |
| Loss per share | $0.12 | $0.09 | Loss increased $0.03 |
| Cash from operations | $(8.072) million | $(4.725) million | Outflow increased $3.347 million |
| Cash balance | $23.014 million | $9.494 million | Increased $13.520 million |
Revenue primarily represented Fiocruz yellow-fever-vaccine technology services. FY2016 revenue and the related research and development expense were each approximately $758,000, resulting in no profit from that arrangement. Research and development expense was $3.156 million versus $3.495 million, while general and administrative expense increased to $7.685 million from $5.022 million, principally because of approximately $3.0 million of iBio CMO-related costs.
Other expense was $764,000 versus other income of $41,000, including $807,000 of interest expense under the iBio CMO capital lease. The company reported no debt-financing balance but had capital lease obligations of $25.435 million, including $170,000 current and $25.265 million long-term.
Total assets were $51.600 million, including $25.574 million of fixed assets and $2.092 million of intangible assets. Total liabilities were $27.556 million. iBio stockholders’ equity was $9.937 million and noncontrolling interest was $14.107 million.
Material Changes Versus Prior Period
- Revenue declined approximately 49% as Fiocruz laboratory tasks neared completion.
- Operating expenses increased approximately 27%, driven by the launch of iBio CMO and higher general and administrative costs.
- Cash increased primarily from $15 million contributed to iBio CMO and approximately $7.2 million received from Eastern for common-stock purchases and warrant exercises.
- Common shares outstanding increased to 89.1 million from 77.2 million, reflecting dilution from Eastern transactions and warrant exercises.
- Eastern’s beneficial ownership increased to approximately 38% of outstanding common stock, subject to a three-year standstill arrangement.
- iBio CMO introduced substantial fixed commitments, including approximately $2.1 million of annual base rent, indexed increases and potential percentage rent.
Outlook, Risks and Unusual Items
Management expected cash on hand at June 30, 2016, together with potential proceeds from the Aspire Capital facility, to fund operations through at least June 30, 2017. No shares had been sold under the $15 million Aspire facility as of the filing date. Management stated that additional capital may still be required beyond that period.
The company has never commercialized a vaccine or therapeutic product and expects continuing losses and negative operating cash flow. IBIO-CFB03 remained in preclinical IND-enabling development. Most other candidates remained preclinical, although certain vaccine candidates had completed or entered Phase 1 studies.
Key risks include dependence on additional financing, potential equity dilution, failure of product candidates or collaborations, regulatory delays, manufacturing and quality-control risks at iBio CMO, competition from better-funded companies, intellectual-property challenges and reliance on third parties.
iBio prevailed on a key ownership issue in its litigation with Fraunhofer: in July 2016, the Delaware Chancery Court held that iBio owns proprietary rights to Fraunhofer plant-based technology developed or held through December 31, 2014. The broader litigation remained unresolved. A securities class-action settlement totaling $1.875 million was approved in April 2016 and funded by insurance. A separate derivative-action settlement remained subject to court approval.
The filing states that the financial statements were prepared on a going-concern basis. Management concluded that disclosure controls and internal control over financial reporting were effective; the external auditor did not provide an internal-control attestation because iBio qualified as a smaller reporting company.
Investor Verification Checklist
- Confirm the filing period and distinguish FY2016 results from any 2015 quarterly period.
- Verify the sustainability and revenue contribution of iBio CMO, including customer contracts and operating capacity.
- Review the capital lease terms, annual rent obligations, percentage-rent provisions and related-party relationships with Eastern affiliates.
- Assess expected cash burn, access to the Aspire facility and the timing and terms of any future financing.
- Track clinical, IND and regulatory progress for IBIO-CFB03 and other product candidates.
- Review the status and potential financial impact of the Fraunhofer and derivative litigation.
- Consider dilution from the 89.1 million shares outstanding, approximately 12.3 million outstanding options and potential future equity issuance.